157 related articles for article (PubMed ID: 27431016)
1. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
[TBL] [Abstract][Full Text] [Related]
2. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
3. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
[TBL] [Abstract][Full Text] [Related]
4. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Georgantopoulos P; Yang H; Norris LB; Bennett CL
Cancer Med; 2019 May; 8(5):2233-2240. PubMed ID: 30983123
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
Trimarco V; Ave E; Facco M; Chiodin G; Frezzato F; Martini V; Gattazzo C; Lessi F; Giorgi CA; Visentin A; Castelli M; Severin F; Zambello R; Piazza F; Semenzato G; Trentin L
Oncotarget; 2015 Dec; 6(39):42130-49. PubMed ID: 26517523
[TBL] [Abstract][Full Text] [Related]
6. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
Filip AA; Grenda A; Popek S; Koczkodaj D; Michalak-Wojnowska M; Budzyński M; Wąsik-Szczepanek E; Zmorzyński S; Karczmarczyk A; Giannopoulos K
Ann Hematol; 2017 Jan; 96(1):33-50. PubMed ID: 27730344
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?
Van Roosbroeck K; Calin GA
Semin Oncol; 2016 Apr; 43(2):209-14. PubMed ID: 27040698
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.
Zaitseva L; Murray MY; Shafat MS; Lawes MJ; MacEwan DJ; Bowles KM; Rushworth SA
Oncotarget; 2014 Oct; 5(20):9930-8. PubMed ID: 25294819
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib in the real world patient: many lights and some shades.
Ghia P; Cuneo A
Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711
[No Abstract] [Full Text] [Related]
10. A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score.
Koyuncu İ; Koyuncu B; Uğur MC; Koyun E; Şenöz O; Doğduş M; Bilgir O
Turk J Haematol; 2024 May; 41(2):91-96. PubMed ID: 38721568
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib Regimens in Older Patients with Untreated CLL.
Diker O
N Engl J Med; 2019 Apr; 380(17):1679. PubMed ID: 31018078
[No Abstract] [Full Text] [Related]
12. Ibrutinib Regimens in Older Patients with Untreated CLL.
Mercier T; Janssens A; Maertens J
N Engl J Med; 2019 Apr; 380(17):1679-1681. PubMed ID: 31018080
[No Abstract] [Full Text] [Related]
13. Ibrutinib Regimens in Older Patients with Untreated CLL.
Sengar M; Gogtay N; Jain H
N Engl J Med; 2019 Apr; 380(17):1679. PubMed ID: 31018079
[No Abstract] [Full Text] [Related]
14. Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Shadman M; Tedeschi A; Mohseninejad L; Yang K; Lamanna N; Xu S; Cohen A; Challagulla S; Xue M; Williams R; O'Brien SM; Brown JR; Tam C
Blood Cancer J; 2024 May; 14(1):77. PubMed ID: 38697986
[No Abstract] [Full Text] [Related]
15. An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program.
Sica A; Sagnelli C; Papa A; Ciccozzi M; Sagnelli E; Calogero A; Martinelli E; Casale B
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32188040
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of microRNAs-143 and -145 in B-cell malignancies.
Akao Y; Nakagawa Y; Kitade Y; Kinoshita T; Naoe T
Cancer Sci; 2007 Dec; 98(12):1914-20. PubMed ID: 17892514
[TBL] [Abstract][Full Text] [Related]
17. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.
Bordini J; Lenzi C; Frenquelli M; Morabito A; Pseftogas A; Belloni D; Mansouri L; Tsiolas G; Perotta E; Ranghetti P; Gandini F; Genova F; Hägerstrand D; Gavriilidis G; Keisaris S; Pechlivanis N; Davi F; Kay NE; Langerak AW; Pospisilova S; Scarfò L; Makris A; Psomopoulos FE; Stamatopoulos K; Rosenquist R; Campanella A; Ghia P
Leukemia; 2024 Jun; 38(6):1287-1298. PubMed ID: 38575671
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib in CLL: benefit for all?
Cuneo A; Ghia P
Blood; 2024 Apr; 143(16):1558-1559. PubMed ID: 38635254
[No Abstract] [Full Text] [Related]
19. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia.
Shalek AK; Gaublomme JT; Wang L; Yosef N; Chevrier N; Andersen MS; Robinson JT; Pochet N; Neuberg D; Gertner RS; Amit I; Brown JR; Hacohen N; Regev A; Wu CJ; Park H
Nano Lett; 2012 Dec; 12(12):6498-504. PubMed ID: 23190424
[TBL] [Abstract][Full Text] [Related]
20. An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.
Alharthi A; Beck D; Howard DR; Hillmen P; Oates M; Pettitt A; Wagner SD
BMC Res Notes; 2018 May; 11(1):280. PubMed ID: 29739419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
